Navigation Links
No Benefit to Lowering Blood Pressure in Acute Stroke: Study
Date:2/11/2011

By Steven Reinberg
HealthDay Reporter

FRIDAY, Feb. 11 (HealthDay News) -- Giving medication to lower blood pressure in hypertensive stroke patients appears to have no benefit and might even be harmful, says a new study that seems to confirm current treatment guidelines.

"Clinicians should not be prescribing blood-pressure-lowering drugs within the first week of acute stroke in routine practice, but researchers should continue to evaluate the safety and effectiveness of other interventions for blood pressure in acute stroke," said Dr. Graeme J. Hankey, head of the Stroke Unit at Royal Perth Hospital in Australia, who is familiar with the study.

Researchers looked at the effect of the blood pressure-lowering drug candesartan on about 1,000 acute stroke patients. Their findings are published online Feb. 11 in The Lancet to coincide with presentation of the study at the International Stroke Conference in Los Angeles.

When added to the results of 10 previous trials, this study indicates that lowering blood pressure in the first week after acute stroke has no overall benefit on subsequent outcome, said Hankey, author of an accompanying journal editorial.

Doctors have been unsure how to treat high blood pressure in acute stroke patients, and current guidelines recommend leaving it alone.

For the study, a multicenter team led by Dr. Eivind Berge from Oslo University Hospital Ulleval in Norway randomly assigned 2,029 acute stroke patients to take candesartan (Atacand) or a placebo. Candesartan belongs to a family of drugs called angiotensin-receptor blockers.

Over a week, the drug significantly lowered the blood pressure of patients receiving it. However, over six months no difference emerged between the two groups in the risk of death, heart attack or stroke, the researchers found.

Moreover, patients taking the drug tended to have poorer outcomes, compared with patients receiving placebo, although this finding was not statistically significant, Berge's group says.

Among those taking candesartan, nine had symptoms associated with low blood pressure, compared with five patients taking placebo. In addition, 18 patients taking candesartan suffered kidney failure, compared with 13 patients receiving placebo, the researchers note.

Berge's team reviewed other studies, which also showed that lowering blood pressure in acute stroke patients had no benefit.

"Other trials are ongoing, but until these trials have been completed we see no place for routine blood pressure-lowering treatment in the acute phase of stroke," the researchers conclude.

Commenting on the study, Dr. Larry B. Goldstein, professor of neurology and director of the Duke Stroke Center at Duke University Medical Center , said that "the optimal treatment of elevated blood pressure in the setting of acute ischemic stroke has been uncertain because of a lack of adequate controlled trials."

Current guidelines recommend that blood pressure should generally not be lowered during the acute phase of ischemic stroke, because doing so might compromise circulation to the damaged brain. "This study supports these existing recommendations," he said.

More information

For more information on stroke, visit the U.S. National Library of Medicine.

SOURCES: Larry B. Goldstein, M.D., professor, neurology, and director, Duke Stroke Center, Duke University Medical Center, Durham, N.C.; Graeme J. Hankey, M.D., consultant neurologist and head, Stroke Unit, Royal Perth Hospital and University of Western Australia, Perth; Feb. 11, 2011, The Lancet, online


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Children With Cerebral Palsy Benefitting From New Physical Therapy Regimen
2. Kaiser Permanente Approves $170 Million in Community Benefit Grants in 2009
3. Survival benefit with high-intensity end-of-life approaches
4. Alzheimers Foundation of America Applauds Social Security for Speeding Disability Benefits for Early-Onset Alzheimers Disease
5. Businesses Rally Big Efforts to Benefit the Susan G. Komen Phoenix Affiliates Fight Against Breast Cancer
6. News brief: Benefit of HPV Vaccination, Frequent Screening for Women over 41 is Likely to be Low
7. 1Dental.com Enhances Dental Plan Benefits With New Fee Schedule
8. AMERICAN IDOL to Benefit the UN Foundation Fund for Haiti Thursday, February 25, on FOX
9. Freedom Healthnet Affirms Affordable Private Health Insurance Benefits
10. Statins May Benefit Prostate Cancer Patients
11. PCMA: Proposed Overhaul of FEHBP Pharmacy Benefit Would Undermine Cost-Saving Tools, Reduce Choices for 8 Million Americans
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
No Benefit to Lowering Blood Pressure in Acute Stroke: Study 
(Date:9/21/2017)... ... September 21, 2017 , ... Promotional Communication:, ... http://www.fdanews.com/products/54818-promotional-communication      , In the competitive world of drug and device marketing and ... compliance with FDA rules. , The FDA has issued two draft guidances that ...
(Date:9/21/2017)... ... September 21, 2017 , ... In addition to sticking with ... more holistic approach and use natural alternatives for all house cleaning products, disinfectants, ... USDA guaranteeing that, the new line of essential oils, are all 100% organic ...
(Date:9/21/2017)... ... September 21, 2017 , ... Japanese Zen artist couple, ... Revolution” on 6th, 7th and 8th October at Miranda Kuo Gallery on Lower East ... pieces, such as Zen Kodo mat. Wanderlust , one of the largest US ...
(Date:9/21/2017)... ... September 21, 2017 , ... ... serving communities in northern Alabama and Georgia, is embarking on an extended charity ... utilizing modern early detection methods. , US Breast Cancer statistics show that ...
(Date:9/20/2017)... ... September 20, 2017 , ... Collins Concrete ... for clients that rely on safety and cleanliness. This unique flooring system uses ... has been used for centuries for its antimicrobial properties. Unlike antibiotics, which kill ...
Breaking Medicine News(10 mins):
(Date:9/12/2017)... , Sept. 12, 2017   EcoVadis , the leading platform ... published the first annual edition of its Global CSR Risk and Performance ... evaluated by EcoVadis, based on Scorecard Ratings that analyzed nearly 800,000 data ... ... ...
(Date:9/9/2017)... Sept. 9, 2017  Eli Lilly and Company (NYSE: ... secondary endpoint data for lasmiditan, an investigational, oral, first-in-class ... statistically significant improvements compared to placebo in the Phase ... at the 18th Congress of the International Headache Society ... "The data presented today demonstrate lasmiditan,s potential to reduce ...
(Date:9/7/2017)... Ind. , Sept. 7, 2017  Zimmer Biomet ... in musculoskeletal healthcare, today announced that it will be ... Global Healthcare Conference at the Grand Hyatt hotel in ... 11, 2017 at 11:40 a.m. Eastern Time. ... via Zimmer Biomet,s Investor Relations website at http://investor.zimmerbiomet.com ...
Breaking Medicine Technology: